GeoVax Labs
GeoVax Labs Inc.: A biotech firm specializing in the development and commercialization of vaccines for HIV-1 and other diseases.
Founded
2001GeoVax Labs Inc.: A biotech firm specializing in the development and commercialization of vaccines for HIV-1 and other diseases.
GeoVax Labs Inc., founded with a mission to serve humanity through innovations in immunology, is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. Utilizing novel proprietary platforms, GeoVax's product portfolio includes Gedeptin®, aimed at treating advanced head and neck cancers, and GEO-CM04S1, a next-generation COVID-19 vaccine currently in Phase II clinical trials. The company targets both the biomedical and pharmaceutical markets with its cutting-edge solutions.
Notable figures affiliated with GeoVax include key researchers and scientists who drive their innovative programs. The company has garnered attention from investors interested in pioneering healthcare solutions. GeoVax's achievements include advancing their oncology and infectious disease programs to critical clinical trial phases, demonstrating significant potential in addressing unmet medical needs. Their impact is marked by contributions to vaccine development and cancer treatment, positioning them as a significant player in the biotech industry.
Companies similar to GeoVax Labs include Dynavax Technologies, Novavax, Agilvax and X-Vax Technology.
GeoVax Labs was founded in 2001.
GeoVax Labs' headquarters is located in Smyrna, GA, US.
GeoVax Labs' most recent funding round was for $10M (USD) in January 2022.
As of Jan 14, 2022, GeoVax Labs has disclosed funding of $28M (USD). Undisclosed round amounts are excluded.
GeoVax Labs has 14 employees as of Feb 6, 2024.
X-Vax Technology
x-vax.com
